Results 281 to 290 of about 576,830 (304)

Interleukin-21: a double-edged sword with therapeutic potential

Nature Reviews Drug Discovery, 2014
Warren J Leonard
exaly  

Interleukin 13 cloning from DA rats

Transplantation Proceedings, 1999
X Y, He, N, Verma, K, Plain, B M, Hall
openaire   +2 more sources

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies

Lancet, The, 2012
Daniel F Freitag, Peter Willeit, Pei Gao
exaly  

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

Lancet, The, 2012
Daniel I Swerdlow, Michael V Holmes, Karoline B Kuchenbaecker   +2 more
exaly  

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

Lancet, The, 2008
Josef S Smolen, Andrea Rubbert-Roth, César R Ramos-Remus   +2 more
exaly  

[Interleukin-13 and interleukin-13 receptor in Hodgkin's disease].

Polskie Archiwum Medycyny Wewnetrznej, 2003
Zofia Monika, Rupniewska, Małgorzata, Wach   +1 more
openaire   +1 more source

Interleukin-22: Immunobiology and Pathology

Annual Review of Immunology, 2015
Jarrod A Dudakov, Alan Hanash, Marcel R M Van Den Brink   +2 more
exaly  

A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

New England Journal of Medicine, 1987
W M Linehan
exaly  

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2015
Philip J Mease, Bruce W Kirkham, Arthur Kavanaugh   +2 more
exaly  

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

Lancet, The, 2013
Antoinette Moran, Linda A Dimeglio, Carla J Greenbaum   +2 more
exaly